Terms: = Lymphoma AND HOXD13, SPD, 3239, P35453, HOX4I
50 results:
1. Correlation between PD-1 and spd-L1 expression levels in peripheral blood of DLBCL patients and their clinicopathological characteristics.
Wang L; Cao C; Qiu J; Zhang J; He Q; Song L; Xie L; Ma J
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):44-50. PubMed ID: 38430041
[TBL] [Abstract] [Full Text] [Related]
2. [Levels and Clinical Significances of spd-1 and spd-L1 in Peripheral Blood of lymphoma Patients].
Liu XL; He P; Lei J; Zou LX; Peng L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1733-1738. PubMed ID: 38071053
[TBL] [Abstract] [Full Text] [Related]
3. Expression of PD-1/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin's lymphoma.
Feng X; Luo X; Yang Y; Fan Y; Ye Q
Medicine (Baltimore); 2023 Nov; 102(44):e35757. PubMed ID: 37933048
[TBL] [Abstract] [Full Text] [Related]
4. Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.
Hirayama AV; Kimble EL; Wright JH; Fiorenza S; Gauthier J; Voutsinas JM; Wu Q; Yeung CCS; Gazeau N; Pender BS; Kirchmeier DR; Torkelson A; Chutnik AN; Cassaday RD; Chapuis AG; Green DJ; Kiem HP; Milano F; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
Blood Adv; 2024 Jan; 8(2):453-467. PubMed ID: 37903325
[TBL] [Abstract] [Full Text] [Related]
5. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
Schiller GJ; Lipe BC; Bahlis NJ; Tuchman SA; Bensinger WI; Sutherland HJ; Lentzsch S; Baljevic M; White D; Kotb R; Chen CI; Rossi A; Biran N; LeBlanc R; Grosicki S; Martelli M; Gunsilius E; Špička I; Stevens DA; Facon T; Mesa MG; Zhang C; Van Domelen DR; Bentur OS; Gasparetto C
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e286-e296.e4. PubMed ID: 37393120
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic value of soluble programmed cell death ligand-1 (spd-L1) in lymphoma: a systematic review and meta-analysis.
Ding Y; Sun C; Hu L; Xiong S; Zhai Z
Ann Hematol; 2023 Sep; 102(9):2425-2434. PubMed ID: 37382610
[TBL] [Abstract] [Full Text] [Related]
7. Randomized crossover trial of 'Roll-over' technique of abdominal paracentesis versus standard technique in suspected malignant ascites.
Jha DK; Rohilla M; Das CK; Irrinki S; Singh H; Arora A; Saha SC; Gupta P; Mandavdhare HS; Dutta U; Sharma A; Sharma V
Expert Rev Gastroenterol Hepatol; 2023 Mar; 17(3):295-300. PubMed ID: 36795510
[TBL] [Abstract] [Full Text] [Related]
8. Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.
Cheng CL; Yao CY; Huang PH; Yu CW; Fang WQ; Chuang WH; Wu SJ; Lin YJ; Hung YC; Tsai CH; Yu SC; Chou WC; Tien HF
Br J Haematol; 2023 Apr; 201(1):75-85. PubMed ID: 36480431
[TBL] [Abstract] [Full Text] [Related]
9. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.
Jiang VC; Hao D; Jain P; Li Y; Cai Q; Yao Y; Nie L; Liu Y; Jin J; Wang W; Lee HH; Che Y; Dai E; Han G; Wang R; Rai K; Futreal A; Flowers C; Wang L; Wang M
Mol Cancer; 2022 Sep; 21(1):185. PubMed ID: 36163179
[TBL] [Abstract] [Full Text] [Related]
10. Development of Aging-Related Emphysematous and lymphoma-Like Lesions is Enhanced by the Lack of Secretoglobin 3A2 in Mouse Lungs.
Kurotani R; Kurumazuka A; Sakahara S; Takakura K; Yokoyama Y; Xu L; Dai J; Lee MP; Kumaki N; Abe H; Kimura S
Int J Chron Obstruct Pulmon Dis; 2022; 17():1247-1260. PubMed ID: 35651829
[TBL] [Abstract] [Full Text] [Related]
11. Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA.
Ruiz IC; Martelli M; Sehn LH; Vitolo U; Nielsen TG; Sellam G; Bottos A; Klingbiel D; Kostakoglu L
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e804-e814. PubMed ID: 35595618
[TBL] [Abstract] [Full Text] [Related]
12. Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma.
Li JW; Shi D; Wan XC; Hu J; Su YF; Zeng YP; Hu ZJ; Yu BH; Zhang QL; Wei P; Zhou XY
Oncoimmunology; 2021; 10(1):1995166. PubMed ID: 34745768
[TBL] [Abstract] [Full Text] [Related]
13. Mutant
Goldberg L; Negi V; Chung YJ; Onozawa M; Zhu YJ; Walker RL; Pierce R; Patel DP; Krausz KW; Gonzalez FJ; Goodell MA; Rodriguez BAT; Meltzer PS; Aplan PD
Cancer Res; 2021 Oct; 81(19):5033-5046. PubMed ID: 34321240
[TBL] [Abstract] [Full Text] [Related]
14. PD1/PD-L1 Expressions in Plasmablastic lymphoma with Clinicopathological Correlation.
Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
[TBL] [Abstract] [Full Text] [Related]
15. Soluble programmed cell death protein 1 (spd-1) and the soluble programmed cell death ligands 1 and 2 (spd-L1 and spd-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract] [Full Text] [Related]
16. A Systemic Protein Deviation Score Linked to PD-1
Ask EH; Tschan-Plessl A; Gjerdingen TJ; Sætersmoen ML; Hoel HJ; Wiiger MT; Olweus J; Wahlin BE; Lingjærde OC; Horowitz A; Cashen AF; Watkins M; Fehniger TA; Holte H; Kolstad A; Malmberg KJ
Med; 2021 Feb; 2(2):180-195.e5. PubMed ID: 35590201
[TBL] [Abstract] [Full Text] [Related]
17. FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of
Løndalen A; Blakkisrud J; Revheim ME; Madsbu UE; Dahle J; Kolstad A; Stokke C
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1902-1914. PubMed ID: 33196921
[TBL] [Abstract] [Full Text] [Related]
18. Clinicopathological Features, Treatment Strategy, and Prognosis of Primary Non-Hodgkin's lymphoma of the Duodenum: A SEER Database Analysis.
Zheng G; Wang Y; Zhao Y; Zheng Z
Can J Gastroenterol Hepatol; 2020; 2020():9327868. PubMed ID: 32399459
[TBL] [Abstract] [Full Text] [Related]
19. Serum levels of soluble programmed death-ligand 1 (spd-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
[TBL] [Abstract] [Full Text] [Related]
20. A unique mutator phenotype reveals complementary oncogenic lesions leading to acute leukemia.
Yin M; Baslan T; Walker RL; Zhu YJ; Freeland A; Matsukawa T; Sridharan S; Nussenzweig A; Pruitt SC; Lowe SW; Meltzer PS; Aplan PD
JCI Insight; 2019 Dec; 4(23):. PubMed ID: 31622281
[TBL] [Abstract] [Full Text] [Related]
[Next]
